NRx Pharmaceuticals, Inc. (NRXP): Price and Financial Metrics


NRx Pharmaceuticals, Inc. (NRXP): $0.53

-0.04 (-7.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NRXP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NRXP Stock Price Chart Interactive Chart >

Price chart for NRXP

NRXP Price/Volume Stats

Current price $0.53 52-week high $26.24
Prev. close $0.58 52-week low $0.49
Day low $0.51 Volume 2,985,100
Day high $0.58 Avg. volume 930,289
50-day MA $1.93 Dividend yield N/A
200-day MA $5.76 Market Cap 35.63M

NRx Pharmaceuticals, Inc. (NRXP) Company Bio


NRX Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company specializes in researching investigational medicines and is engaged in the development of medicines and vaccines for Covid-19, other respiratory conditions, suicidal depression, and PTSD.


NRXP Latest News Stream


Event/Time News Detail
Loading, please wait...

NRXP Latest Social Stream


Loading social stream, please wait...

View Full NRXP Social Stream

Latest NRXP News From Around the Web

Below are the latest news stories about NRX Pharmaceuticals Inc that investors may wish to consider to help them evaluate NRXP as an investment opportunity.

How Much Of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Do Insiders Own?

Every investor in NRx Pharmaceuticals, Inc. ( NASDAQ:NRXP ) should be aware of the most powerful shareholder groups...

Yahoo | February 21, 2022

NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment

NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today announced results of a review conducted by the Therapeutics and Prevention Data Safety and Monitoring Board (DSMB) of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) on February 14, 2022. The DSMB reviewed data on 448 ICU patients with Critical COVID-19 Respiratory Failure who were enrolled in the ACTIV-3b (TESICO) trial1. The TESICO protocol was sub

Yahoo | February 15, 2022

NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine

Remarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaperBriLife vaccine may have better neurtralizing ability against Omicron variant than first generation mRNA vaccines, according to IIBR findings RADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel Yitzhaki, Director of the Israel Institute for Biological Research, who spoke at the Eli Hurvitz Institute f

Yahoo | February 11, 2022

NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq Rules

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP (or the "Company"), a Delaware corporation, today announced that it has closed its previously announced private placement priced at a premium to market under Nasdaq rules of 7,824,727 shares of its common stock and unregistered preferred investment options (the "investment options") to purchase up to an aggregate of 7,824,727 shares of common stock. The purchase price for one share of common stock and one investment option to purchase one share of common s

Yahoo | February 3, 2022

NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 7,824,727 shares of common stock in a private placement priced at a premium to market under Nasdaq rules. The Company will also issue to the investors unregistered preferred investment options (the "investment options") to purchase up to an aggregate of 7,824,727 shares of common stock. The purchase price for one share of c

Yahoo | January 31, 2022

Read More 'NRXP' Stories Here

NRXP Price Returns

1-mo -66.03%
3-mo -82.27%
6-mo -92.07%
1-year -97.59%
3-year N/A
5-year N/A
YTD -88.91%
2021 -80.41%
2020 130.19%
2019 3.92%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5101 seconds.